NYSE - Delayed Quote • USD
Eli Lilly and Company (LLY)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 7:58 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 16 | 16 | 25 | 25 |
Avg. Estimate | 2.46 | 2.77 | 12.5 | 18.19 |
Low Estimate | 2.22 | 2.45 | 11.86 | 14.65 |
High Estimate | 2.78 | 3.03 | 13.5 | 20.58 |
Year Ago EPS | 1.62 | 2.11 | 6.32 | 12.5 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 16 | 14 | 25 | 25 |
Avg. Estimate | 8.92B | 9.86B | 41.44B | 51.46B |
Low Estimate | 8.51B | 9.55B | 40.4B | 45.94B |
High Estimate | 9.23B | 10.33B | 43.57B | 55.87B |
Year Ago Sales | 6.96B | 8.31B | 34.12B | 41.44B |
Sales Growth (year/est) | 28.20% | 18.60% | 21.40% | 24.20% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | 1.73 | 1.98 | -0.13 | 2.22 |
EPS Actual | 1.62 | 2.11 | 0.1 | 2.49 |
Difference | -0.11 | 0.13 | 0.23 | 0.27 |
Surprise % | -6.40% | 6.60% | 176.90% | 12.20% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 2.46 | 2.77 | 12.5 | 18.19 |
7 Days Ago | 2.47 | 2.77 | 12.51 | 18.29 |
30 Days Ago | 2.29 | 2.48 | 11.22 | 16.33 |
60 Days Ago | 2.24 | 2.42 | 11.02 | 15.93 |
90 Days Ago | 2.46 | 2.7 | 12.45 | 17.73 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | 1 | -- | 1 | -- |
Up Last 30 Days | 2 | 4 | 3 | 6 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 1 | 1 | 2 | 3 |
Growth Estimates
CURRENCY IN USD | LLY | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 51.90% | -- | -- | 1.50% |
Next Qtr. | 31.30% | -- | -- | 11.40% |
Current Year | 97.80% | -- | -- | 5.20% |
Next Year | 45.50% | -- | -- | 13.40% |
Next 5 Years (per annum) | 50.67% | -- | -- | 11.09% |
Past 5 Years (per annum) | -4.62% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/18/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/15/2024 |
Maintains | Goldman Sachs: Neutral to Neutral | 4/11/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 |
Upgrade | Erste Group: Hold to Buy | 4/3/2024 |
Maintains | Citigroup: Buy to Buy | 4/2/2024 |
Related Tickers
PFE Pfizer Inc.
26.27
-0.19%
JNJ Johnson & Johnson
148.53
-0.69%
ABBV AbbVie Inc.
167.80
-1.03%
MRK Merck & Co., Inc.
127.00
+0.09%
AMGN Amgen Inc.
273.01
-0.19%
BMY Bristol-Myers Squibb Company
48.86
-0.27%
GILD Gilead Sciences, Inc.
67.08
+0.07%
NVS Novartis AG
98.35
+1.10%
BIIB Biogen Inc.
201.99
+4.56%
AZN AstraZeneca PLC
71.20
+0.49%